How has Dogwood Therapeutics's other commercial liabilities changed year-over-year?

Dogwood Therapeutics's other commercial liabilities increased by 70.8% year-over-year, from $1.38M to $2.35M.

What is the long-term trend for Dogwood Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), Dogwood Therapeutics's other commercial liabilities has grown at a 23.4% compound annual growth rate (CAGR), from $784.1K to $2.24M.

Dogwood Therapeutics DWTX Other Commercial Liabilities

Other Commercial Liabilities at other companies

Vertex PharmaceuticalsVRTX

——

Collegium Pharmaceutical, Inc.COLL

——

BioventusBVS

——

Avanos MedicalAVNS

——

LON

LeonaBio, Inc. Common StockLONA

——

Amylyx Pharmaceuticals, Inc.AMLX

——

Other financials

Income statement

See full

Operating income-$5.1M-14.6%

Net income-$5.0M+54.4%

EPS (diluted)-$0.15+98.2%

Balance sheet

See full

Cash & equivalents$13.2M-24.6%

Total debt$144.9K-24.2%

Total equity$80.6M+1,038%

Total assets$95.2M-1.8%

Cash flow

See full

Operating cash flow-$4.6M+2.0%

Valuation

See full

Market cap$54.14M-54.2%

Enterprise value$41.06M-60.9%

Returns & leverage

See full

Return on equity-64.6%-29.8pp

Debt / equity0×0.0×

Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dogwood Therapeutics's other commercial liabilities?: Dogwood Therapeutics (DWTX) reported other commercial liabilities of $2.35M in Q1 2026.
How has Dogwood Therapeutics's other commercial liabilities changed year-over-year?: Dogwood Therapeutics's other commercial liabilities increased by 70.8% year-over-year, from $1.38M to $2.35M.
What is the long-term trend for Dogwood Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), Dogwood Therapeutics's other commercial liabilities has grown at a 23.4% compound annual growth rate (CAGR), from $784.1K to $2.24M.